Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Case Study
  • Published:

Treatment of amiodarone-associated thyrotoxicosis

Nature Clinical Practice Endocrinology & Metabolism volume 3, pages 662–666 (2007)Cite this article

Abstract

Background A 75-year-old man had a myocardial infarction complicated by poor left ventricular function and non-sustained ventricular tachycardia. He began treatment with amiodarone and 12 months later developed symptoms of thyrotoxicosis.

Investigations Thyroid function tests after commencement of amiodarone revealed a high-normal level of free T4 and low-normal level of free T3 with a normal serum TSH. When symptoms of thyrotoxicosis developed, significant rises in T4 and T3 levels and suppression of TSH were observed. Thyroid autoantibodies were detected and thyroid ultrasonography revealed a small multinodular goiter.

Diagnosis Amiodarone-induced thyrotoxicosis (AIT) with features consistent with both AIT type I (in which thyroid antibodies and nodular goiter are present) and AIT type II (which is not responsive to thionamide therapy and eventually leads to permanent hypothyroidism).

Management The patient continued to be treated with amiodarone. He commenced thionamide (carbimazole) therapy but failed to improve, even after a dose increase. Glucocorticoid (prednisolone) therapy was therefore added. Combination therapy was associated with gradual clinical and biochemical improvement. The patient became persistently hypothyroid after stopping thionamide and glucocorticoid therapy and was stabilized on long-term thyroxine replacement.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Time course of the changes in thyroid function tests (serum levels of free T4, free T3 and TSH) and of the treatment with carbimazole and prednisolone in the patient described

References

  1. Newman CM et al. (1998) Amiodarone and the thyroid: a practical guide to the management of thyroid dysfunction induced by amiodarone therapy. Heart 79: 121–127

    Article  CAS  Google Scholar 

  2. Martino E et al. (2001) The effects of amiodarone on the thyroid. Endocr Rev 22: 240–254

    CAS  PubMed  Google Scholar 

  3. Davies PH et al. (1992) Treatment of amiodarone induced thyrotoxicosis with carbimazole alone and continuation of amiodarone. BMJ 305: 224–225

    Article  CAS  Google Scholar 

  4. Smyrk TC et al. (1987) Pathology of the thyroid in amiodarone-associated thyrotoxicosis. Am J Surg Pathol 11: 197–204

    Article  CAS  Google Scholar 

  5. Osman F et al. (2002) Successful treatment of amiodarone-induced thyrotoxicosis. Circulation 105: 1275–1277

    Article  CAS  Google Scholar 

  6. Eaton SE et al. (2002) Clinical experience of amiodarone-induced thyrotoxicosis over a 3-year period: role of colour-flow Doppler sonography. Clin Endocrinol (Oxf) 56: 33–38

    Article  CAS  Google Scholar 

  7. Basaria S and Cooper DS (2005) Amiodarone and the thyroid. Am J Med 118: 706–714

    Article  CAS  Google Scholar 

  8. Daniels GH (2001) Amiodarone-induced thyrotoxicosis. J Clin Endocrinol Metab 86: 3–8

    Article  CAS  Google Scholar 

  9. Martino E et al. (1988) Radioactive iodine thyroid uptake in patients with amiodarone-iodine-induced thyroid dysfunction. Acta Endocrinol (Copenh) 119: 167–173

    Article  CAS  Google Scholar 

  10. Bogazzi F et al. (1997) Color flow Doppler sonography rapidly differentiates type I and type II amiodarone-induced thyrotoxicosis. Thyroid 7: 541–545

    Article  CAS  Google Scholar 

  11. Bartalena L et al. (2004) Diagnosis and management of amiodarone-induced thyrotoxicosis in Europe: results of an international survey among members of the European Thyroid Association. Clin Endocrinol (Oxf) 61: 494–502

    Article  Google Scholar 

  12. Osman F et al. (2007) Cardiovascular manifestations of hyperthyroidism before and after antithyroid therapy: a matched case–control study. J Am Coll Cardiol 49: 71–81

    Article  CAS  Google Scholar 

  13. Hermida JS et al. (2004) Radioiodine ablation of the thyroid to allow the reintroduction of amiodarone treatment in patients with a prior history of amiodarone-induced thyrotoxicosis. Am J Med 116: 345–348

    Article  CAS  Google Scholar 

  14. Bogazzi F et al. (2007) Glucocorticoid response to amiodarone-induced thyrotoxicosis due to destructive thyroiditis is predicted by thyroid volume and serum free thyroid hormone concentrations. J Clin Endocrinol Metab 92: 556–562

    Article  CAS  Google Scholar 

  15. Bogazzi F et al. (2003) Treatment of type II amiodarone-induced thyrotoxicosis by either iopanoic acid or glucocorticoids: a prospective, randomized study. J Clin Endocrinol Metab 88: 1999–2002

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Medical Sciences, JA Franklyn is a Professor of Medicine and Associate Dean for the Graduate School, and MD Gammage is a Reader in Cardiovascular Medicine, The Medical School, University of Birmingham, UK.,

    Jayne A Franklyn & Michael D Gammage

Authors
  1. Jayne A Franklyn
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael D Gammage
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jayne A Franklyn.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Franklyn, J., Gammage, M. Treatment of amiodarone-associated thyrotoxicosis. Nat Rev Endocrinol 3, 662–666 (2007). https://doi.org/10.1038/ncpendmet0592

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpendmet0592

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing